HC Wainwright Cuts Earnings Estimates for Nuvation Bio

Nuvation Bio Inc. (NYSE:NUVB) – Equities research analysts at HC Wainwright dropped their Q3 2025 earnings estimates for Nuvation Bio in a report issued on Thursday, January 23rd. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.16) per share for the quarter, down from their prior estimate of ($0.14). HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Nuvation Bio’s Q4 2025 earnings at ($0.15) EPS and FY2025 earnings at ($0.62) EPS.

Nuvation Bio (NYSE:NUVB) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The business had revenue of $0.73 million during the quarter.

Other equities analysts have also issued reports about the stock. Wedbush reaffirmed an “outperform” rating and set a $5.00 target price on shares of Nuvation Bio in a research report on Monday, January 6th. Royal Bank of Canada restated an “outperform” rating and set a $10.00 price objective (up from $6.00) on shares of Nuvation Bio in a research note on Tuesday, January 7th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $8.20.

Nuvation Bio Stock Down 9.2 %

Shares of NUVB opened at $2.52 on Monday. Nuvation Bio has a 52-week low of $1.52 and a 52-week high of $4.16. The company has a market cap of $846.47 million, a PE ratio of -1.16 and a beta of 1.47. The business has a fifty day moving average of $2.74 and a 200 day moving average of $2.79.

Institutional Trading of Nuvation Bio

Large investors have recently made changes to their positions in the business. Frazier Life Sciences Management L.P. purchased a new stake in shares of Nuvation Bio in the third quarter worth about $2,790,000. Dimensional Fund Advisors LP lifted its holdings in Nuvation Bio by 415.2% during the second quarter. Dimensional Fund Advisors LP now owns 1,018,329 shares of the company’s stock valued at $2,975,000 after purchasing an additional 820,669 shares in the last quarter. Wexford Capital LP grew its position in shares of Nuvation Bio by 930.2% in the third quarter. Wexford Capital LP now owns 651,767 shares of the company’s stock valued at $1,493,000 after purchasing an additional 588,500 shares during the period. FMR LLC increased its stake in shares of Nuvation Bio by 1.4% during the third quarter. FMR LLC now owns 29,238,871 shares of the company’s stock worth $66,957,000 after purchasing an additional 416,932 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Nuvation Bio by 479.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 442,913 shares of the company’s stock worth $1,014,000 after purchasing an additional 366,429 shares during the last quarter. 61.67% of the stock is owned by hedge funds and other institutional investors.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.